Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis

NeuroImmunoModulation

Volumn 17, Issue 4, 2010, Pages 252-264

  Hasseldam, Henrik ^a   Johansen, Flemming Fryd ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cannabinoids; Cytokines; Experimental autoimmune encephalomyelitis; Hypothermia; Multiple sclerosis; Neuroimmunomodulation; Neuroprotection

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HISTOPATHOLOGY; IMMUNOMODULATION; INFLAMMATION; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NERVE FIBER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RELAPSE; T LYMPHOCYTE; TH17 CELL;

ANIMALS; BENZOXAZINES; CYTOKINES; CYTOPROTECTION; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOMODULATION; MICROGLIA; MORPHOLINES; MULTIPLE SCLEROSIS; NAPHTHALENES; NEUROPROTECTIVE AGENTS; NEUROTRANSMITTER AGENTS; RATS; T-LYMPHOCYTES; TREATMENT OUTCOME; WALLERIAN DEGENERATION;

EID: 77950106481     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000290041     Document Type: Article

References (67)

1. Trapp BD, Ransohoff R, Rudick R: Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999; 12: 295-302.
2. Lassmann H: Multiple sclerosis: is there neurodegeneration independent from inflammation? J Neurol Sci 2007; 259: 3-6.
3. Klein TW, Newton C, Larsen K, et al: The cannabinoid system and immune modulation. J Leukoc Biol 2003; 74: 486-496.
4. Maresz K, Pryce G, Ponomarev ED, et al: Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells. Nat Med 2007; 13: 492-497.
5. Bonfils PK, Reith J, Hasseldam H, et al: Estimation of the hypothermic component in neuroprotection provided by cannabinoids following cerebral ischemia. Neurochem Int 2006; 49: 508-518.
6. Panikashvili D, Simeonidou C, Ben Shabat S, et al: An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001; 413: 527-531.
7. Baker D, Pryce G, Croxford JL, et al: Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 2001; 15: 300-302.
8. Ni X, Geller EB, Eppihimer MJ, et al: Win 55212-2, a cannabinoid receptor agonist, attenuates leukocyte/endothelial interactions in an experimental autoimmune encephalomyelitis model. Mult Scler 2004; 10: 158-164.
9. Croxford JL, Miller SD: Immunoregulation of a viral model of multiple sclerosis using the synthetic cannabinoid R+WIN55,212. J Clin Invest 2003; 111: 1231-1240.
10. Jackson SJ, Pryce G, Diemel LT, et al: Cannabinoid- receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience 2005; 134: 261-268.
11. Palazuelos J, Davoust N, Julien B, et al: The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008; 283: 13320-13329.
12. Croxford JL, Pryce G, Jackson SJ, et al: Cannabinoid- mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis. J Neuroimmunol 2008; 193: 120-129.
13. Maldonado R: Study of cannabinoid dependence in animals. Pharmacol Ther 2002; 95: 153-164.
14. Petitet F, Jeantaud B, Bertrand P, et al: Cannabinoid penetration into mouse brain as determined by ex vivo binding. Eur J Pharmacol 1999; 374: 417-421.
15. McPartland JM, Glass M, Pertwee RG: Metaanalysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol 2007; 152: 583-593.
16. Begolka WS, Vanderlugt CL, Rahbe SM, et al: Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis. J Immunol 1998; 161: 4437-4446.
17. Novelli F, Conti L, Clerico M, et al: Type I IFN inhibits the expansion of Th17 lymphocytes from both healthy subjects and multiple sclerosis patients. FASEB J 2008; 22: 1069.6.
18. Amor S, Groome N, Linington C, et al: Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 1994; 153: 4349-4356.
19. Schwab S, Schwarz S, Aschoff A, et al: Moderate hypothermia and brain temperature in patients with severe middle cerebral artery infarction. Acta Neurochir Suppl 1998; 71: 131-134.
20. Johansen FF, Jorgensen HS, Reith J: Prolonged drug-induced hypothermia in experimental stroke. J Stroke Cerebrovasc Dis 2003; 12: 97-102.
21. Jorgensen SH, Jensen PE, Laursen H, et al: Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. Neurol Res 2005; 27: 591-597.
22. Heckl S, Nagele T, Herrmann M, et al: Experimental autoimmune encephalomyelitis (EAE): lesion visualization on a 3 Tesla clinical whole-body system after intraperitoneal contrast injection. Rofo 2004; 176: 1549-1554.
23. Rogge L, Papi A, Presky DH, et al: Antibodies to the IL-12 receptor beta 2 chain mark human Th1 but not Th2 cells in vitro and in vivo. J Immunol 1999; 162: 3926-3932.
24. Barkhof F: The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002; 15: 239-245.
25. Juhler M, Barry DI, Offner H, et al: Bloodbrain and blood-spinal cord barrier permeability during the course of experimental allergic encephalomyelitis in the rat. Brain Res 1984; 302: 347-355.
26. Murphy LL, Munoz RM, Adrian BA, et al: Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 1998; 5: 432-446.
27. Burgos E, Pascual D, Isabel Martín M, et al: Antinociceptive effect of the cannabinoid agonist, WIN 55,212-222, in the orofacial and temporomandibular formalin tests. Eur J Pain, E-pub ahead of print.
28. Bolton C, O'Neill JK, Allen SJ, et al: Regulation of chronic relapsing experimental allergic encephalomyelitis by endogenous and exogenous glucocorticoids. Int Arch Allergy Immunol 1997; 114: 74-80.
29. Zajicek J, Fox P, Sanders H, et al: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo- controlled trial. Lancet 2003; 362: 1517-1526.
30. Zajicek JP, Sanders HP, Wright DE, et al: Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005; 76: 1664-1669.
31. Katona S, Kaminski E, Sanders H, et al: Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exp Immunol 2005; 140: 580-585.
32. Collin C, Davies P, Mutiboko IK, et al: Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 2007; 14: 290-296.
33. Rog DJ, Nurmikko TJ, Young CA: Oromucosalδ 9 -tetrahydrocannabinol/ cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007; 29: 2068-2079.
34. Liblau RS, Singer SM, McDevitt HO: Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases. Immunol Today 1995; 16: 34-38.
35. Baron JL, Madri JA, Ruddle NH, et al: Surface expression of alpha 4 integrin by CD4 T cells is required for their entry into brain parenchyma. J Exp Med 1993; 177: 57-68.
36. Issazadeh S, Lorentzen JC, Mustafa MI, et al: Cytokines in relapsing experimental autoimmune encephalomyelitis in DA rats: persistent mRNA expression of proinflammatory cytokines and absent expression of interleukin-10 and transforming growth factor- beta. J Neuroimmunol 1996; 69: 103-115.
37. Buntinx M, Moreels M, Vandenabeele F, et al: Cytokine-induced cell death in human oligodendroglial cell lines: I. Synergistic effects of IFN-gamma and TNF-alpha on apoptosis. J Neurosci Res 2004; 76: 834-845.
38. Downen M, Amaral TD, Hua LL, et al: Neuronal death in cytokine-activated primary human brain cell culture: role of tumor necrosis factor-alpha. Glia 1999; 28: 114-127.
39. Wheeler RD, Owens T: The changing face of cytokines in the brain: perspectives from EAE. Curr Pharm Des 2005; 11: 1031-1037.
40. Bettelli E, Nicholson LB: The role of cytokines in experimental autoimmune encephalomyelitis. Arch Immunol Ther Exp (Warsz) 2000; 48: 389-398.
41. Segal BM: Experimental autoimmune encephalomyelitis: cytokines, effector T cells, and antigen-presenting cells in a prototypical Th1-mediated autoimmune disease. Curr Allergy Asthma Rep 2003; 3: 86-93.
42. Imitola J, Chitnis T, Khoury SJ: Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther 2005; 106: 163-177.
43. Chu CQ, Wittmer S, Dalton DK: Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192: 123-128.
44. Eugster HP, Frei K, Bachmann R, et al: Severity of symptoms and demyelination in MOGinduced EAE depends on TNFR1. Eur J Immunol 1999; 29: 626-632.
45. Bachmann R, Eugster HP, Frei K, et al: Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide- induced chronic demyelinating autoimmune encephalomyelitis in mice. Am J Pathol 1999; 154: 1417-1422.
46. Berner V, Liu H, Zhou Q, et al: IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med 2007; 13: 354-360.
47. Arnett HA, Mason J, Marino M, et al: TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001; 4: 1116-1122.
48. Mestre L, Correa F, Revalo-Martin A, et al: Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis. J Neurochem 2005; 92: 1327-1339.
49. Shibaki A, Katz SI: Induction of skewed Th1/ Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant. Exp Dermatol 2002; 11: 126-134.
50. Rabchevsky AG, Degos JD, Dreyfus PA: Peripheral injections of Freund's adjuvant in mice provoke leakage of serum proteins through the blood-brain barrier without inducing reactive gliosis. Brain Res 1999; 832: 84-96.
51. McGeachy MJ, Anderton SM: Cytokines in the induction and resolution of experimental autoimmune encephalomyelitis. Cytokine 2005; 32: 81-84.
52. von Budingen HC, Tanuma N, Villoslada P, et al: Immune responses against the myelin/ oligodendrocyte glycoprotein in experimental autoimmune demyelination. J Clin Immunol 2001; 21: 155-170.
53. Srivastava MD, Srivastava BI, Brouhard Bδ 9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998; 40: 179-185.
54. Sacerdote P, Martucci C, Vaccani A, et al: The nonpsychoactive component of marijuana cannabidiol modulates chemotaxis and IL-10 and IL-12 production of murine macrophages both in vivo and in vitro. J Neuroimmunol 2005; 159: 97-105.
55. Xiao BG, Bai XF, Zhang GX, et al: Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J Neuroimmunol 1998; 84: 230-237.
56. Ozenci V, Kouwenhoven M, Huang YM, et al: Multiple sclerosis is associated with an imbalance between tumour necrosis factoralpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferonbeta (IFN-beta) treatment. Clin Exp Immunol 2000; 120: 147-153.
57. Zhang X, Koldzic DN, Izikson L, et al: IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells. Int Immunol 2004; 16: 249-256.
58. Raine CS, Cannella B, Hauser SL, et al: Demyelination in primate autoimmune encephalomyelitis and acute multiple sclerosis lesions: a case for antigen-specific antibody mediation. Ann Neurol 1999; 46: 144-160.
59. Langrish CL, Chen Y, Blumenschein WM, et al: IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
60. Komiyama Y, Nakae S, Matsuki T, et al: IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177: 566-573.
61. Miljkovic D, Stosic-Grujicic S, Markovic M, et al: Strain difference in susceptibility to experimental autoimmune encephalomyelitis between Albino Oxford and Dark Agouti rats correlates with disparity in production of IL-17, but not nitric oxide. J Neurosci Res 2006; 84: 379-388.
62. Page G, Sattler A, Kersten S, et al: Plasma cell-like morphology of Th1-cytokine-producing cells associated with the loss of CD3 expression. Am J Pathol 2004; 164: 409-417.
63. Matusevicius D, Kivisakk P, He B, et al: Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101-104.
64. Barnett MH, Henderson AP, Prineas JW: The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult Scler 2006; 12: 121-132.
65. McGavern DB, Murray PD, Rivera-Quinones C, et al: Axonal loss results in spinal cord atrophy, electrophysiological abnormalities and neurological deficits following demyelination in a chronic inflammatory model of multiple sclerosis. Brain 2000; 123: 519-531.
66. Arevalo-Martin A, Vela JM, Molina-Holgado E, et al: Therapeutic action of cannabinoids in a murine model of multiple sclerosis. J Neurosci 2003; 23: 2511-2516.
67. Wujek JR, Bjartmar C, Richer E, et al: Axon loss in the spinal cord determines permanent neurological disability in an animal model of multiple sclerosis. J Neuropathol Exp Neurol 2002; 61: 23-32.